Hjem › Pankreaskreft › California › Orange
Kliniske studier for Pankreaskreft i Orange, CA
15 studier for Pankreaskreft søker deltakere på steder i og rundt Orange (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
RekruttererFase 1
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RekruttererFase 2/3
- UC Irvine Health, Orange
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
RekruttererFase 3
- Investigative Site US049, Orange
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
RekruttererFase 3
- UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- UC IRVINE Health, Orange
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
RekruttererFase 1
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
RekruttererFase 1/2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
Rekrutterer
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
RekruttererFase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Pancreatic Cancer Early Detection Consortium
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- UC Irvine Health, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RekruttererFase 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RekruttererFase 1/2
- UC Irvine/Chao Family Comprehensive Cancer Center, Orange
PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)
RekruttererFase 1
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Orange
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RekruttererFase 1/2
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
Pankreaskreft-studier i andre byer
- Houston, TX61 studier
- New York City, NY60 studier
- Boston, MA43 studier
- Nashville, TN39 studier
- Los Angeles, CA35 studier
- St. Louis, MO33 studier
- Arlington, VA33 studier
- Baltimore, MD31 studier
- San Antonio, TX31 studier
- Philadelphia, PA26 studier
- Tampa, FL26 studier
- Durham, NC24 studier
Andre studier i Orange
- Ikke-småcellet lungekreft25 studier
- Metastatisk kreft20 studier
- Kolorektal kreft16 studier
- Eggstokkreft16 studier
- Melanom14 studier
- Leverkreft (hepatocellulært karcinom)14 studier
- Brystkreft14 studier
- Lungekreft14 studier
- Prostatakreft14 studier
- Mavekreft13 studier
- Kreft (alle typer)13 studier
- Akut myelogen leukemi13 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.